Newsbenzinga
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results
· Published
Article summary
Jazz Pharmaceuticals (JAZZ) reported Q2 sales above estimates and raised its FY26 sales guidance. Analysts have mixed opinions, with some raising price targets. Consider buying JAZZ stock.
An excerpt from the original article.
Comments —
Loading comments…